A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of siponimod along with influenza and pneumococcal (PPV-23) vaccine in healthy volunteers

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of siponimod along with influenza and pneumococcal (PPV-23) vaccine in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2016

At a glance

  • Drugs Siponimod (Primary) ; Influenza virus vaccine; Pneumococcal vaccine
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 04 May 2016 New trial record
    • 21 Apr 2016 Results of effect of siponimod treatment on vaccination-induced immune response (n=136) were presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top